Making a Real Impact on

Severe Human Diseases

and Patient’s Life

Establishing a Pipeline of Differentiated Drug Candidates

OMEICOS’ pipeline is based on our proprietary approach that targets one of nature’s most important cell-protective pathways combined with industry-leading knowledge of omega-3 fatty acid metabolism and biology. Using these capabilities, we have established a broad compound library, are evaluating selected compounds in a number of therapeutic applications.

Due to the cardioprotective, neuroprotective, anti-inflammatory, anti-fibrotic and immune-modulating properties of the compounds, this could open up novel therapeutic concepts for the prevention and treatment of several diseases.

Pipeline

OMT-28, a Phase 2 Clinical Candidate ready for evaluation in CV Inflammation and Mitochondriopathies

Our most advanced therapeutic candidate, OMT-28, has completed a Phase 2 clinical study for the prevention of atrial fibrillation. While the impact on atrial fibrillation was not sufficient to progress this indication, OMT-28 demonstrated a positive impact on a number of inflammatory biomarkers such as IL-6. In addition, OMT-28 has confirmed an excellent safety profile in both Phase 1 & 2 clinical trials.

These data, together with pre-clinical data showing anti-inflammatory and anti-atherosclerotic effects support the potential of OMT-28 in the treatment of cardiometabolic syndromes. We are actively planning a proof of concept clinical study in patients with coronary artery disease on biomarkers of cardiovascular inflammation. In independent outcome studies, a reduction of these biomarkers has been directly associated with positive clinical outcomes.

OMEICOS is also actively planning a clinical program in cardiomyopathy associated with rare mitochondrial diseases such as MELAS, Friedreich’s Ataxia and Duchenne Muscular Dystrophy based on positive data on mitochondrial function in relevant models.

OMT-28 is a stable synthetic small molecule analog of the natural omega-3 fatty acid metabolite 17,18-EEQ, which has a structure optimized to provide high efficacy, safety and oral bioavailability. Our compound has already proven its  cardioprotective and anti-fibrotic potential in different in vivo models.

In a previously performed Phase 1 study, OMT-28 exhibited an excellent tolerability profile and showing no safety signals in vital signs or safety laboratory parameters up to the maximum dose tested of 60 mg.
This excellent overall and also cardiovascular safety profile has been confirmed in our Phase 2 study with atrial fibrillation patients.

 

Broadening the Pipeline in Ophthalmology

In addition to the company’s development activities in the cardiovascular space, OMEICOS has begun branching out into additional indications, initially focusing on severe eye disorders.

Exploratory work with OMEICOS’ therapeutic candidates included the generation of preclinical data comparing our approach to the current standard-of-care, injections of anti-VEGF therapies directly into the eye.

In a widely used mouse model for wet AMD, the choroidal neovascularization (CNV) model, OMEICOS’ approach reduced the formation of abnormal blood vessels and the leakiness of these blood vessels that is typical for wet AMD. The therapeutic effects of our approach observed in this model were comparable with the anti-VEGF therapy used, in this case Aflibercept. Taking into account that therapeutic compounds based on OMEICOS’ technology have the potential to be conveniently given to patients as a pill, avoiding the need for injections into the eye, these results provide a very solid basis for further development in these indications.